agilon health, inc. (AGL) Stock Forecast
AGL analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.60 / 5 from 15 analysts
- Price target
- $115.83 average of analyst targets
- Upside to target
- +36.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-2.01
- 52-week range
- $7.91 – $129.84
AGL analyst ratings
15 analystsNumber of analysts at each rating.
AGL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AGL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.73 | −$1.36 | −$0.25 | −$6.40 | +88.6% | 6 |
| Current fiscal year (2026) | −$1.79 | −$5.34 | $2.07 | −$23.75 | +92.5% | 11 |
| Next fiscal year (2027) | $2.36 | −$2.38 | $6.15 | −$0.16 | +1,591.5% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AGL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.46B | $1.45B | $1.48B | +1.8% | 13 |
| Current fiscal year (2026) | $5.83B | $5.78B | $5.89B | −1.8% | 14 |
| Next fiscal year (2027) | $6.24B | $5.99B | $6.61B | +7.0% | 14 |
AGL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AGL revenue: reported and forecast
AGL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.65 | −$0.74 | −$0.75 | −$0.64 | −$0.73 | +12.4% | 2 up · 4 down |
| Current fiscal year (2026) | −$2.93 | −$2.08 | −$1.60 | −$1.79 | −$1.79 | −39.1% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.62 | $1.32 | $1.76 | $2.40 | $2.36 | −480.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AGL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AGL beat in 4 of 12.
What analysts expect from AGL
15 analysts cover agilon health; their consensus rating is buy (3.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $115.83, 36.1% above the latest close of $85.12. Analysts expect earnings of −$1.79 per share for 2026, +92.5% from a year earlier. For 2027 the average estimate is $2.36 per share on revenue of $6.2 billion. agilon health beat the EPS estimate in 4 of the last 12 quarters.
Related: AGL income statement, AGL key metrics, AGL chart. See the AGL stock overview for the latest quote and news.
AGL forecast FAQ
What is agilon health's price target?
The average analyst price target for agilon health is $115.83, 36.1% above the latest close of $85.12.
Is agilon health a buy, hold or sell?
Of 15 analysts covering agilon health, 5 rate it a strong buy, 0 a buy, 9 a hold, 1 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is agilon health's EPS forecast?
Analysts forecast −$1.79 per share for 2026 (range −$5.34 to $2.07); for 2027 the estimate is $2.36.
What is agilon health's revenue forecast?
The average revenue estimate for 2026 is $5.8 billion, growth of −1.8%; for 2027 it is $6.2 billion.
When does agilon health report earnings?
agilon health is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-2.01.
Does agilon health usually beat earnings estimates?
agilon health reported EPS at or above the analyst estimate in 4 of the last 12 quarters.